Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Submits New Amyvid Data For Medicare National Coverage Analysis

This article was originally published in The Pink Sheet Daily

Executive Summary

Physicians in study changed their diagnosis of whether a patient had Alzheimer’s in half of cases after receiving data from PET scans using Lilly’s beta amyloid detecting tracer Amyvid. Study findings were not available when Lilly first asked CMS to conduct the coverage analysis.


Related Content

Medicare Panel Finds Little Support For Amyloid PET Imaging Changes
Medicare Part B: Commentary By CMS Officials
Medicare Coverage Decision For Amyvid Due July 2013
Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts